Search

Highlights: [•] Alzheimer's disease: the state of the drug discovery art. [•] Acetylcholinesterase inhibitors in therapy. [•] New enzymatic targets and inhibitors/enhancers. [•] Secretases, sirtuins, caspases, glycogen synthase kinase-3. [•] Autophagy and synaptogenesis inhibitors/enhancers. [ABSTRACT FROM AUTHOR]

Hepatocarcinogenesis is a complex multistep process in which many different molecular pathways have been implicated. Hepatocellular carcinoma (HCC) is refractory to conventional chemotherapeutic agents, and the new targeted therapies are meeting with limited success. Interreceptor crosstalk and the positive feedback between different signaling systems are emerging as mechanisms of targeted therapy resistance. The identification of such interactions is therefore of particular relevance to improve therapeutic efficacy. Among the different signaling pathways activated in hepatocarcinogenesis the epidermal growth factor receptor (EGFR) system plays a prominent role, being recognized as a "signaling hub" where different extracellular growth and survival signals converge. EGFR can be transactivated in response to multiple heterologous ligands through the physical interaction with multiple receptors, the activity of intracellular kinases or the shedding of EGFR-ligands. In this article we review the crosstalk between the EGFR and other signaling pathways that could be relevant to liver cancer development and treatment. [ABSTRACT FROM AUTHOR]